AOD 9604s evidence base comes primarily from animal studies Both peptides operate through entirely different biological mechanisms, making a direct comparison challenging AOD 9604 vs Tirzepatide: The Core Difference AOD 9604 is a modified fragment of human growth hormone (specifically amino acids 176-191 with an additional N-terminal tyrosine residue) engineered to isolate the lipolytic domain of hGH while avoiding broader growth hormone receptor activation
Indoor or night-shift work
Additionally, peptides like SS-31 can also influence growth factors, promoting cellular growth and repair
[7] Commonly observed adverse effects include transient injection-site discomfort, breast tenderness, nausea, fluid retention, and mild mood fluctuation, whereas rarer but serious events encompass venous or arterial thromboembolism, gallbladder disease, significant elevation of blood pressure, and hormone-sensitive malignancies such as endometrial or breast cancer